


#2

PATENT

IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE

Applicants: Erik H.F. Wong *et al.* ) I hereby certify that this paper is being  
Serial No.: To be assigned ) deposited with the United States Postal Service  
Filed: January 23, 2002 (Herewith) ) on January 23, 2002, in an envelope  
Title: METHODS OF TREATING ) addressed to the Box Patent Application,  
AND PREVENTING ) Commissioner for Patents, Washington, D.C.  
INCONTINENCE (*As amended*) ) 20231 utilizing the "Express Mail Post Office  
Group Art Unit: To be assigned ) to Addressee" service of the United States  
Examiner: To be assigned ) Postal Service under Mailing Label No.  
Attorney Docket No.: 6248.8 ) EK657825134US..

11002 U.S. PTO  
10/055663  
01/23/02

  
Richard Zimmermann

INFORMATION DISCLOSURE STATEMENT

Box Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith for consideration by the examiner is a Form PTO-1449, which identifies publications which may be considered material to the examination of the above-identified application.

Copies of the following publications are being submitted herewith, and are identified in the accompanying Form PTO-1449:

1. U.S. Patent No. 4,596,807;
2. International Publication No. WO 96/12485;
3. International Publication No. WO 97/35584;
4. International Publication No. WO 97/35586;
5. M. Max et al., "Efficacy of Desipramine in Painful Diabetic Neuropathy: A Placebo-Controlled Trial," *Pain*, Vol. 45, No. 1, pp. 3-10 (1991);
6. M. Max et al., "Effects of Desipramine Amitriptyline and Fluoxetine on Pain in Diabetic Neuropathy," *New Engl. J. Med.*, Vol. 326, No. 19, pp. 1250-1256 (1992);
7. M. Max, "Treatment of Post-Herpetic Neuralgia: Antidepressants," *Ann. Neurol.*, Vol. 35, Suppl., pp. s50-s53 (1994);

8. W. Reimann et al., "Inhibition of Spinal Noradrenaline Uptake in Rats by the Centrally Acting Analgesic Tramadol," *Biochem. Pharmacol.*, Vol. 47, No. 12, pp. 2289-2293 (1994);
9. Dostert et al., "Review of the Pharmacokinetics and Metabolism of Reboxetine, a Selective Noradrenaline Reuptake Inhibitor," *Euro. Neuropsychopharmacol.*, Vol. 7, Suppl. 1, pp. s23-s35 (1997);
10. M. Owens et al., "Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites," *J. Pharmacol. Exp. Ther.*, Vol. 283, pp. 1305-1322 (1997);
11. K. Moore et al., "Tissue Distribution of Tramadol and Metabolites in an Overdose Fatality," *Am. J. of Forensic Med. and Path.*, Vol. 20, No. 1, pp. 98-100 (1999); and,
12. International Preliminary Examination Report in PCT/US/017256 dated December 19, 2001.

In accordance with 37 C.F.R. § 1.98(d), copies of the other publications identified in the Form PTO-1449 are not being submitted herewith, as copies of these publications were supplied to the Patent Office and cited in information disclosure statements submitted in the parent application (Wong et al. U.S. Serial No. 09/599,213 filed June 22, 2000), or cited by the Patent Office in a FORM PTO-892. The parent application is being relied upon for an earlier effective filing date under 35 U.S.C. § 120.


An early and favorable action on the merits is respectfully requested.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

January 23, 2002

By

  
Sandip H. Patel (Reg. No. 43,848)  
Attorneys for Applicants  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6357  
(312) 474-6300 (Telephone)  
(312) 474-0448 (Facsimile)